Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women

28 juli 2026 uppdaterad av: Abdelrahman Farid Adam Senosy, Al-Azhar University

Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females

Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.

This study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.

A total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.

Symptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.

The study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypten, 11511
        • Ain Shams University Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Female participants aged 18 to 70 years.
  • Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.
  • Failure of behavioral therapy and medical treatment for overactive bladder.
  • Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Current use of medical treatment for overactive bladder.
  • Cardiac pacemaker or metallic implant in the treatment area.
  • Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.
  • Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.
  • Urinary bladder stones.
  • Post-void residual urine volume greater than 100 mL.
  • Lower urinary tract surgery within the previous 6 months.
  • Previous pelvic radiation therapy.
  • History of neuropathic disease.
  • Pregnancy or planning to become pregnant.
  • Hepatic, renal, or cardiac impairment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Active Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive active low-intensity extracorporeal shock wave therapy using the PiezoWave 2 focused extracorporeal shock wave therapy device. Treatment will be administered once weekly for 6 weeks. Before each session, participants will drink 1000 mL of water, and treatment will begin when the bladder reaches approximately 50% of the participant's functional bladder capacity, confirmed by bladder scan. The probe will be placed over the lower abdomen approximately two fingerbreadths above the pubic symphysis and directed toward the bladder dome and bilateral bladder walls. Each session will deliver 1000 impulses to each target area, for a total of 3000 impulses, at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
Focused low-intensity extracorporeal shock wave therapy will be delivered using the PiezoWave 2 device. Each session will deliver a total of 3000 impulses at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second. Treatment will be administered once weekly for 6 weeks.
Sham Comparator: Sham Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive a sham procedure once weekly for 6 weeks. The procedure will be similar to the active treatment in participant positioning, bladder preparation, probe placement, session duration, and device sound. A sham probe or zero-energy device setting will be used so that no therapeutic shock wave energy is delivered.
A sham procedure will be administered using the same treatment setup, participant positioning, probe placement, session duration, and device sound as active therapy. A sham probe or zero-energy setting will be used so that no therapeutic shock wave energy is delivered. The procedure will be performed once weekly for 6 weeks.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overactive Bladder Questionnaire 8-Item Total Score
Tidsram: Baseline and 1 month after completion of the 6-week treatment
The Arabic-validated Overactive Bladder Questionnaire 8-Item (OAB-V8) will be completed at baseline and 1 month after completion of treatment. The questionnaire contains 8 items scored from 0 to 5, giving a total score ranging from 0 to 40. Higher scores indicate greater symptom-related bother. The outcome will be calculated as the change in total OAB-V8 score from baseline to the 1-month assessment.
Baseline and 1 month after completion of the 6-week treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Post-Void Residual Urine Volume at 3 Months
Tidsram: Baseline and 3 months after completion of treatment
Post-void residual urine volume will be measured by ultrasound after urination and recorded in milliliters. The outcome will be calculated as the change from baseline to the 3-month follow-up assessment.
Baseline and 3 months after completion of treatment
Urinary Frequency Recorded in a 3-Day Voiding Diary
Tidsram: Baseline and 3 months after completion of treatment
Participants will record the timing and number of urination episodes in a 3-day voiding diary. The outcome will assess the change in urinary frequency from baseline to the 3-month follow-up assessment.
Baseline and 3 months after completion of treatment
Mean Voided Urine Volume Recorded in a 3-Day Voiding Diary
Tidsram: Baseline and 3 months after completion of treatment
The volume of urine passed during each urination will be recorded in milliliters in a 3-day voiding diary. Mean voided volume will be calculated, and the change from baseline to the 3-month follow-up assessment will be evaluated.
Baseline and 3 months after completion of treatment
Urgency Level Recorded in a 3-Day Voiding Diary
Tidsram: Baseline and 3 months after completion of treatment
Participants will record the level of urinary urgency associated with each urination episode in a 3-day voiding diary. The outcome will assess the change in recorded urgency level from baseline to the 3-month follow-up assessment.
Baseline and 3 months after completion of treatment
Urinary Leakage Episodes Recorded in a 3-Day Voiding Diary
Tidsram: Baseline and 3 months after completion of treatment
The number of involuntary urinary leakage episodes will be recorded over 3 consecutive days. The outcome will be calculated as the change in the number of leakage episodes from baseline to the 3-month follow-up assessment.
Baseline and 3 months after completion of treatment
Functional Bladder Capacity
Tidsram: Baseline and 3 months after completion of treatment
Functional bladder capacity will be derived from measurements recorded in the participant's 3-day voiding diary and expressed in milliliters. The outcome will assess the change from baseline to the 3-month follow-up assessment.
Baseline and 3 months after completion of treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2026

Primärt slutförande (Beräknad)

1 februari 2027

Avslutad studie (Beräknad)

1 februari 2027

Studieregistreringsdatum

Först inskickad

28 juli 2026

Först inskickad som uppfyllde QC-kriterierna

28 juli 2026

Första postat (Faktisk)

31 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

31 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 juli 2026

Senast verifierad

1 juli 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera